Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvemcitug + Chemotherapy in Platinum-Resistant Ovarian Cancer
NCT03763123Phase 1Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Apr 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suvemcitug in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 3 years and Ratio of Adverse Events at 3 years. Status: unknown.
02
Drugs
suvemcitug
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03763123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03763123.